Employees: 2,012
Size RPG Life Sciences (RPGLIFE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $443M, the 904th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,502 on 18 Nov 2026.
Performance Over six months the shares gained 9.6%, against -18.4% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 14.7% over the last twelve months (peer median +8.5%); the operating margin is 17.3% (peer median 3.3%).
Valuation It trades at 5.3× enterprise value to sales against a peer median of 2.6× (5th most expensive of 21).
Capital Return on invested capital runs 0.9 points below its cost of capital (13.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹7.64B | ₹7.04B | ₹6.50B | ₹5.79B | ₹5.10B |
| Revenue growth | — | +8% | +12% | +13% | — |
| Gross profit | ₹3.21B | ₹2.44B | ₹2.45B | ₹2.07B | ₹1.70B |
| EBITDA | ₹1.56B | ₹1.47B | ₹1.60B | ₹1.27B | ₹1.03B |
| Net income | ₹1.09B | ₹1.15B | ₹1.83B | ₹877M | ₹676M |
| Free cash flow | n/a | -₹800,000 | ₹444M | ₹261M | ₹606M |
| Capital expenditure | n/a | ₹654M | ₹360M | ₹692M | ₹327M |
| Total debt | ₹264M | ₹200M | ₹0 | ₹0 | ₹100,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RPGLIFE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.0% | -10.9% | 9th lowest of 21 |
| 6-month return | +9.6% | -18.4% | 2nd highest of 21 |
| Distance from 52-week high | -20.0% | -43.9% | 3rd highest of 21 |
| Revenue growth (TTM) | +14.7% | +8.5% | 9th highest of 21 |
| Operating margin | 17.3% | 3.3% | 3rd highest of 21 |
| EV / Sales | 5.3× | 2.6× | 5th most expensive of 21 |
| ROIC minus cost of capital | -0.9 pp | -1.6 pp | 10th highest of 20 |
| EV / EBITDA | 25.9× | 14.5× | most expensive of 4 |
| Net debt / EBITDA | -1.7× | 2.0× | least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| RPG Life Sciences RPGLIFE.NS | India | $443M | +10% | +15% | 17% | 5.3× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $441M | -25% | -14% | 0% | 0.2× | -9.9% | -3.4% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $445M | -21% | +5% | 19% | 3.4× | 1.3% | +1.3% |
| Dong-A Socio 000640.KS | South Korea | $447M | -8% | +11% | 7% | 0.7× | -6.6% | +12.8% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $437M | -16% | -5% | -29% | 4.2× | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | 2.1× | -5.6% | -5.6% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | 10.6× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $449M | -21% | -9% | 5% | 2.4× | 4.5% | +3.3% |
| Gufic Biosciences GUFICBIO.NS | India | $452M | +48% | +17% | 14% | 4.3× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 2.9× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 1.1× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 3.4× | -0.2% | +14.5% |
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 2.9× | n/a | n/a |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | 2.2× | 1.4% | -1.3% |
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | 2.2× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | 1.2× | 10.6% | +1.4% |
| Zota Health Care ZOTA.NS | India | $427M | +9% | +69% | -16% | 6.2× | n/a | n/a |
| Ovid Therapeutics OVID | United States | $427M | -5% | -78% | -4,700% | 208.3× | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | 164.0× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | 2.2× | 5.4% | +15.3% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 0.2× | n/a | n/a |